Weave Communications, Inc.
Weave Communications, Inc. (WEAV) is listed on NYSE and classified in Health Information Services, part of the Healthcare sector. It is headquartered in Lehi, United States and has 904 employees. The company is worth $594.53M. Revenue was $239.02M in fiscal 2025, up 17.0% from the year before. It reported a net loss of $28.05M. The share price is 4.0% below its 52-week high of $7.70. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $8.84M. In that quarter, 2 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -58.4% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $7.59 | $15.92 | $11.47 | $4.58 | $15.18 | |
| P/S | 4.7x | 2.5x | 5.8x | 4.7x | 2.1x | 8.5x |
| P/B | 8.7x | 7.2x | 17.6x | 10.3x | 3.6x | 8.7x |
| EPS | -$0.37 | -$0.40 | -$0.46 | -$0.76 | -$2.60 | |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ZVRAZevra Therapeutics Inc | $9.94 | 10.8x | 2.7x | 0.00% | 34.80% | $590.27M |
| IRWDIronwood Pharmaceuticals Inc | $3.57 | 4.6x | — | 0.00% | — | $589.91M |
| AVRAnteris Technologies Global Corp. | $6.05 | — | 2.3x | 0.00% | -74.65% | $589.62M |
| AVTXAvalo Therapeutics, Inc. |
| Profit margin |
| -18.20% |
| -11.74% |
| -13.87% |
| -18.20% |
| -35.00% |
| -44.61% |
| ROE | -42.33% | -34.05% | -42.33% | -39.30% | -59.77% | -46.03% |
Median of the years shown; P/E years above 200x are left out.
| $11.27 |
| — |
| 1.3x |
| 0.00% |
| -36.27% |
| $604.41M |
| NVCTNuvectis Pharma, Inc. | $18.60 | — | 54.7x | 0.00% | -214.58% | $607.18M |
| PBYIPuma Biotechnology Inc | $11.26 | 21.2x | 4.2x | 0.00% | 21.97% | $581.24M |